Merck's 4.8 Trillion Yen Gamble: Acquisition Talks with Revolution Medicines and the Map of Post-Keytruda Supremacy

On January 8, 2026, it was reported that the major U.S. pharmaceutical company Merck (hereinafter, Merck) is in discussions to acquire the cancer drug development biotechnology firm Revolution Medicines (hereinafter, Revolution or RVMD) for a total of $28 billion to $32 billion (approximately 4.2 trillion to 4.8 trillion yen). If this deal is finalized, it would be the largest M&A in the industry since Pfizer's acquisition of Seagen in 2023 ($43 billion), signaling a decisive turning point in capital allocation strategy within the biopharmaceutical sector.